|
|
 FDA Information - January 7, 2009
| The patch contains the popular ADHD drug, Ritalin, and was seen by a Food and Drug Administration official as too risky. However, the reviewer has since reversed his decision | | The patch contains the popular ADHD drug, Ritalin, and was seen by a Food and Drug Administration official as too risky. However, the reviewer has since reversed his decision | | An experimental patch to treat children with attention deficit hyperactivity disorder (ADHD) is safe and effective but should carry certain restrictions, a U.S. advisory panel unanimously said on Friday. The Food and Drug Administration is considering whether to approve the patch, made by Britain's Shire Pharmaceuticals Group Plc and U.S.-based Noven Pharmaceuticals Inc. The FDA usually follows the advice of its advisory panels. The panel is still discussing whether the patch has been proven safe | | The latest proposal for a patch that helps treat children suffering from attention deficit hyperactivity disorder is being interrupted by concerns of The Food and Drug Administration. According to the FDA, there's a problem with the ADHD patch. An FDA scientist has given it a negative review, saying it can't be marketed safely | | Bayer AG announces Monday its Kogenate FS hemophilia treatment, which is administered with a device called Bio-Set, has been approved by the U.S. Food and Drug Administration. The pharmaceutical and medical products firm says the device eliminates the risk of accidental needle-stick injuries during reconstitution of the blood-clotting factor that hemophiliacs take | |
|
|
